Alogliptin (nesina) for Adults with Type-2 Diabetes

Overview

Journal P T

Specialty Pharmacology

Date 2014 May 3

PMID 24790396

Citations 7

Authors

Laura Dineen

Connie Law

Rebecca Scher

Eunice Pyon

Affiliations

Soon will be listed here.

Abstract

Alogliptin (Nesina) for adults with type-2 diabetes.

Citing Articles

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition.

Xie Y, Zhou Q, He Q, Wang X, Wang J Acta Pharm Sin B. 2023; 13(6):2383-2402.

PMID: 37425060 PMC: 10326166. DOI: 10.1016/j.apsb.2022.11.008.

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.

Abdalla M, Deshmukh H, Atkin S, Sathyapalan T Ther Adv Endocrinol Metab. 2021; 12:2042018821989238.

PMID: 33552465 PMC: 7844452. DOI: 10.1177/2042018821989238.

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis.

Shima H, Okamoto T, Tashiro M, Inoue T, Masaki C, Tada H Kidney Med. 2020; 1(2):75-78.

PMID: 32734188 PMC: 7380391. DOI: 10.1016/j.xkme.2019.03.001.

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor.

Gu N, Park S, Chung H, Jin X, Lee S, Kim T Transl Clin Pharmacol. 2020; 28(1):17-33.

PMID: 32274378 PMC: 7136081. DOI: 10.12793/tcp.2020.28.e4.

DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.

Mikov M, Pavlovic N, Stanimirov B, danic M, Golocorbin-Kon S, Stankov K Eur J Drug Metab Pharmacokinet. 2019; 45(1):1-14.

PMID: 31385198 DOI: 10.1007/s13318-019-00570-y.

References

Scheen A . Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12(8):648-58. DOI: 10.1111/j.1463-1326.2010.01212.x. View

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

Golightly L, Drayna C, McDermott M . Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51(8):501-14. DOI: 10.1007/BF03261927. View

Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X . Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2009; 48(1):46-58. DOI: 10.5414/cpp48046. View

Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q . Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010; 33(11):2406-8. PMC: 2963503. DOI: 10.2337/dc10-0159. View

Monami M, Dicembrini I, Mannucci E . Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 16(1):48-56. DOI: 10.1111/dom.12176. View

Rendell M, Drincic A, Andukuri R . Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012; 13(4):553-63. DOI: 10.1517/14656566.2012.656088. View

White W, Bakris G, Bergenstal R, Cannon C, Cushman W, Fleck P . EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in.... Am Heart J. 2011; 162(4):620-626.e1. DOI: 10.1016/j.ahj.2011.08.004. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

10.

Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S . The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013; 14(3):259-67. DOI: 10.1517/14656566.2013.761690. View

11.

Andukuri R, Drincic A, Rendell M . Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2011; 2:117-26. PMC: 3048010. View

12.

White W, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C . Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15(7):668-73. DOI: 10.1111/dom.12093. View

13.

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

14.

Nauck M, Ellis G, Fleck P, Wilson C, Mekki Q . Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63(1):46-55. DOI: 10.1111/j.1742-1241.2008.01933.x. View

15.

Baetta R, Corsini A . Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011; 71(11):1441-67. DOI: 10.2165/11591400-000000000-00000. View

16.

Rosenstock J, Wilson C, Fleck P . Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013; 15(10):906-14. DOI: 10.1111/dom.12102. View

17.

Aroda V, Henry R, Han J, Huang W, DeYoung M, Darsow T . Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012; 34(6):1247-1258.e22. DOI: 10.1016/j.clinthera.2012.04.013. View

18.

DeFronzo R, Fleck P, Wilson C, Mekki Q . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008; 31(12):2315-7. PMC: 2584188. DOI: 10.2337/dc08-1035. View

19.

Bosi E, Ellis G, Wilson C, Fleck P . Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13(12):1088-96. DOI: 10.1111/j.1463-1326.2011.01463.x. View

20.

Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009; 25(10):2361-71. DOI: 10.1185/03007990903156111. View